Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: An analysis of survival in 619 female patients

Lung Cancer

Volumn 57, Issue 2, 2007, Pages 207-212

  Matakidou, Athena ^a   el Galta, Rachid ^a   Webb, Emily L ^a   Rudd, Matthew F ^a   Bridle, Helen ^b   Eisen, Tim ^b   Houlston, Richard S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Arg72Pro polymorphism; Lung cancer; p53; Prognostic marker

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; LOG RANK TEST; LUNG CANCER; MAJOR CLINICAL STUDY; MARKER GENE; NONPARAMETRIC TEST; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANK SUM TEST; STATISTICAL ANALYSIS; TUMOR SUPPRESSOR GENE;

AMINO ACID SUBSTITUTION; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROLINE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447267488     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.02.021     Document Type: Article

References (17)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
3. Wahl G.M., and Carr A.M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3 (2001) E277-E286
4. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6 (2000) 4055-4063
5. Baptiste N., Friedlander P., Chen X., and Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21 (2002) 9-21
6. Sjalander A., Birgander R., Kivela A., and Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45 (1995) 144-149
7. Bonafe M., Salvioli S., Barbi C., Mishto M., Trapassi C., Gemelli C., et al. p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochem Biophys Res Commun 299 (2002) 539-541
8. Sullivan A., Syed N., Gasco M., Bergamaschi D., Trigiante G., Attard M., et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23 (2004) 3328-3337
9. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
10. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
11. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., and Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5 (1999) 129-134
12. Bergamaschi D., Gasco M., Hiller L., Sullivan A., Syed N., Trigiante G., et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3 (2003) 387-402
13. Buller R.E., Sood A., Fullenkamp C., Sorosky J., Powills K., and Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 4 (1997) 239-245
14. Matakidou A., Eisen T., Bridle H., O'Brien M., Mutch R., and Houlston R.S. Case-control study of familial lung cancer risks in UK women. Int J Cancer 116 (2005) 445-450
15. Klein J., and Moeschberger M. Survival analysis: Techniques for censored and truncated data. 1st ed. (1997), Springer, Berlin
16. Tagawa M., Murata M., and Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clinicopathological features. Cancer Lett 128 (1998) 93-99
17. Hu Y., McDermott M.P., and Ahrendt S.A. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11 (2005) 2502-2509